Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Novamont Doubles Production of Biopolyesters

Novamont
Posted on: 30 Nov 17

NOVARA, Italy, November 28, 2017 /PRNewswire/ --

By the end of the first quarter of 2018, the production capacity of the subsidiary MATER-BIOPOLYMER will have increased from 50,000 to 100,000 tonnes/year of ORIGO-BI, the family of high-value polyesters with a high content of renewable raw materials based on biomonomers  

On completing the acquisition of 100% of Mater-Biopolymer from the Mossi & Ghisolfi group in 2016, Novamont launched the second phase of the project to redevelop the Mater-Biopolymer plant in Patrica (FR), doubling the production capacity of the ORIGO-BI family of biopolyesters, used to improve the technical, economic and environmental properties of MATER-Bi® biodegradable and compostable bioplastics. Together with the development of new chemicals and production processes, this has given a strong new impetus to upstream integration of the Novamont production line.

In 2009, the Mater-Biopolymer plant in Patrica belonged to M&G, had two PET production lines and had stopped production on one line. From 2009, a partnership enabled Novamont to start working on gradually converting this line to its technology. In 2011, the first continuous plant for production of ORIGO-BI - biodegradable polyesters obtained from monomers from vegetable oils - was inaugurated. It has since become a flagship plant and a link to the Novamont biorefinery. By the end of the first quarter of 2018, when the process to convert the second line will be completed, and taking full advantage of the technological advances made possible by the experience gained from the first line, Novamont will double production capacity of the ORIGO-BI biopolyester range, from 50,000 to 100,000 tonnes per year and achieving a higher content of renewable raw materials.

According to Novamont's Managing Director Catia Bastioli, "Doubling the production capacity of the Patrica plant is a further step towards building an Italian bioplastic and biochemical supply chain integrating research, agriculture and industry and developing products that can deliver solutions to major environmental problems".

The Novamont circular bioeconomy model is one of the soundest in Europe in terms of investments and new industry-driven technologies, with €500 million invested in plants, directly or in joint ventures, €200 million in research and development, 600 direct and 2,000 indirect workers, 1,000 people involved in construction of 4 new world-class plants, 6 abandoned sites in 6 different regions re-industrialised, developments and impacts for agriculture.

The Novamont Group is world leader in the development and production of bioplastics and biochemicals through the integration of chemistry, the environment and agriculture. With 600 employees, the Group posted sales of €170 million in 2016 and made continuous investments in research and development activities (20% of its staff) and has a portfolio of around 1,000 patents. The group has its headquarters in Novara, a production facility in Terni and research laboratories in Novara, Terni and Piana di Monte Verna (CE). The Novamont subsidiaries are based in Porto Torres (SS), Bottrighe (RO), Terni and Patrica (FR). Active in Germany, France and the United States through commercial offices and a representative office in Brussels (Belgium), Novamont operates through own distributors in Benelux, Scandinavia, Denmark, the United Kingdom, China, Japan, Canada, Australia and New Zealand.  

Press office Novamont: Francesca De Sanctis - francesca.desanctis@novamont.com - tel.: +39-0321-699-611 - cell.: +39-340-1166-426

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 30/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.